|By PR Newswire||
|September 9, 2013 02:01 AM EDT||
CHERTSEY, England, September 9, 2013 /PRNewswire/ --
In liver transplant patients, late renal failure is a significant cause of morbidity and is associated with premature mortality,,
Invasive fungal infections affect between 8.4%-17.7% of liver transplant patients and are associated with a high mortality rate,,,
New data presented at the 16th Congress of the European Society for Organ Transplantation (ESOT) demonstrate that in liver transplant patients, initiating ADVAGRAF™ prolonged-release capsules (tacrolimus) therapy immediately post transplant, at a dose 25% lower than the upper recommended limit, in combination with basiliximab, results in significantly better renal function and a lower incidence of acute organ rejection when compared with standard dose ADVAGRAF therapy. Furthermore, delaying the introduction of ADVAGRAF post transplant gives no additional advantage in terms of renal function.
In a separate study and the largest of its kind, MYCAMINE[TM] (micafungin) was found to be non-inferior to standard of care in preventing fungal infections in liver transplant patients and showed similar safety outcomes.
Results from the DIAMOND (ADVAGRAF studied In combinAtion with MycOphenolate mofetil aND basiliximab in liver transplantation) study show that an initial dose of prolonged-release tacrolimus (0.15-0.175mg/kg/day) plus MMF and induction therapy (without maintenance steroids) resulted in better renal function and a significantly lower incidence of acute rejection over 24 weeks compared to the other regimens; tacrolimus (initial dose: 0.2mg/kg/day) vs tacrolimus (0.2mg/kg/day delayed to day 5) plus basiliximab.
"These data provide new insights and considerations for immunosuppressive treatment in the immediate post-operative period," comments Dr. Ayad Abdulahad, Senior Vice President Medical Affairs and Health Economics, Astellas Pharma Europe Ltd. "Renal function is a vital predictor of long-term transplant success; the DIAMOND study suggests potential for balancing the risk of rejection, whilst minimising the risk of renal damage and potentially reducing the risk of long-term complications. This study shows that lower dose tacrolimus, given immediately post-transplantation, offers the potential advantages of an immunosuppressive regimen which minimises risk of graft rejection whilst preserving renal function without the need for maintenance steroids."
Infections are one of the major complications after transplantation and the incidence of infections in liver transplant patients is higher compared with recipients of other organs. Between 8.4% and 17.7% of liver transplant patients can be affected by fungal infections and these are associated with organ rejection, increased mortality and prolonged stay in the Intensive Care Unit.,,,
In the TENPIN (Liver Transplant EuropeaN Study Into the Prevention of Fungal INfection) study, the first randomised controlled trial of an echinocandin in this setting and the largest study of its kind, micafungin proved to be at least as effective as centre-specific standard of care (fluconazole, liposomal amphotericin B or caspofungin) in the prevention of invasive fungal infections in liver transplant patients. Current guidelines recommend either fluconazole or liposomal amphotericin B for prevention of invasive candidiasis in liver transplantation, and either lipid formulations of amphotericin B or an echinocandin for prevention of invasive aspergillosis. In addition, liver and renal safety of micafungin was also similar to study standard of care.
The TENPIN study included more than 340 liver transplant patients at high-risk of fungal infection, who were randomised to micafungin 100mg (2mg/kg in patients ≤40kg) once daily (n=173) or centre-specific standard of care (fluconazole 200-400mg; liposomal amphotericin B 1-3mg/kg/day; or caspofungin 70mg loading, 50mg maintenance) once daily (n=172). At the end of treatment, 98.6% of patients on micafungin in the Per Protocol population (n=140) were free of invasive fungal infections and had no need for further antifungals compared to 99.3% for standard of care (n=137).
"The low incidence of invasive fungal infections seen in this study clearly demonstrates the value of prophylactic antifungal treatment in high risk liver transplant patients," comments Professor Saliba, Associate Professor in Hepatology and Gastroenterology,Hôpital Paul Brousse Villejuif, France. "With current guideline-recommended treatments having their limitations, with risk of both resistance and drug interactions, micafungin looks to be a welcome and much needed additional treatment option."
NOTES FOR EDITORS
About ADVAGRAF™ and tacrolimus
Tacrolimus is a leading immunosuppressive drug used for the prevention of transplant allograft rejection after organ transplantation. It is available worldwide as a twice-a-day formulation (PROGRAF™) and as a prolonged-release formulation (ADVAGRAF™) which provides the convenience of once-daily dosing with more consistent tacrolimus exposure. Tacrolimus levels require careful management to maintain a minimum exposure of tacrolimus for the prevention of transplant allograft rejection, whilst avoiding excessive levels which may increase the risk of serious side effects. The prolonged-release formulation of ADVAGRAF allows tacrolimus to be available for absorption over a greater proportion of the gastrointestinal tract. This alteration in release profile provides the potential for reduced variability in tacrolimus exposure, achieving and maintaining consistent target trough levels with a reduced requirement for dose adjustments, and improved medication adherence as a single, morning dose., Emerging data indicate that these properties of ADVAGRAF may favourably influence clinical outcomes.
DIAMOND is a multicentre, randomised study involving 901 patients designed to investigate renal function with ADVAGRAF prolonged-release capsules (tacrolimus). Patients received either prolonged-release tacrolimus (0.15-0.175mg/kg/day) and Basiliximab induction therapy; tacrolimus (initial dose: 0.2mg/kg/day) or tacrolimus (0.2mg/kg/day delayed to day 5) plus basiliximab. All patients received MMF and maintenance steroids were not used.
In the study, patients on a lower dose of tacrolimus (0.15-0.175mg/kg/day) plus MMF and induction therapy (without maintenance steroids) had a higher eGFR than those treated with tacrolimus (0.2mg/kg/day) vs tacrolimus (0.2mg/kg/day delayed to day 5) plus basiliximab (76.4 vs 67.4 vs 73.3mL/min/1.73m2). Patients on the lower dose tacrolimus regimen also had a significantly better rejection free survival when compared with other regimens (85.7% vs 79.9% vs 79.6%). Adverse events were comparable between all treatment regimens.
Mycamine is an antifungal of the echinocandin class. In Europe, the indications for adults, adolescents 16 years of age and older, and the elderly are: treatment of invasive candidiasis, treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate, and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count <500 cells/mcL) for 10 or more days.
For children (including neonates) and adolescents younger than 16 years of age, micafungin is indicated for treatment of invasive candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count <500 cells/mcL) for 10 or more days.
TENPIN is an open-label, randomised, multicentre trial involving 345 liver transplant patients. The study was designed to investigate the efficacy and safety of micafungin compared with site-approved standard of care prophylaxis in liver transplant patients at high risk of invasive fungal disease. After transplant, patients were randomised to iv micafungin 100mg once daily (n=173) or iv standard of care according to centre-specific standard protocols (fluconazole 200-400mg once daily or liposomal amphotericin B 1-3mg/kg/day or caspofungin 70mg loading, 50mg maintenance once daily; n=172).
At end of prophylaxis (mean drug duration 17 days), clinical success was 98.6% for micafungin (n=140) and 99.3% for standard of care (n=137) in the Per Protocol population (primary efficacy endpoint). In the Full Analysis population clinical success was 96.5% for micafungin (n=172) and 93.6% for standard of care (n=172). Incidences of drug-related adverse events for micafungin and standard of care were 11.6% and 16.3%, leading to discontinuation in 6.4% and 11.6% of cases, respectively. Liver and renal function were similar between groups.
About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd., located in the UK, is the European headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 4,300 staff across these regions. For more information about Astellas Pharma Europe Ltd., please visit http://www.astellas.eu.
1. Cohen AJ, et al. Chronic Renal Dysfunction Late After Liver Transplantation. Liver Transpl. 2002 Vol 8, No 10 (October): pp 916-921.
2. Fisher NC, et al. Chronic Renal Failure Following Liver Transplantation. Transplantation. 1998; 66:59-66.
3. Ojo AO, et al. Chronic Renal Failure after Transplantation of a Nonrenal Organ. N Engl J Med. 2003; 349:931-40.
4. Vera A, et al. Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundación Santa Fe de Bogotá, Colombia. Transpl Infect Dis. 2011 Dec;13(6):608-15. doi: 10.1111/j.1399-3062.2011.00640.x.
5. Zhou T, et al. Invasive fungal infection after liver transplantation: risk factors and significance of immune cell function monitoring. J Dig Dis. 2011 Dec;12(6):467-75. doi: 10.1111/j.1751-2980.2011.00542.x.
6. Pacholczyk M, et al. Invasive fungal infections following liver transplantation - risk factors, incidence and outcome. Ann Transplant. 2011 Jul-Sep;16(3):14-6.
7. Raghuram A, et al. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007). Liver Transpl. 2012 Sep;18(9):1100-9. doi: 10.1002/lt.23467.
8. European Public Assessment Report (EPAR). Advagraf. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000712/WC500022235.pdf. Last accessed August 2013.
9. Trunecka P et al. Preserving Renal Function with Prolonged-Release Tacrolimus-Baesd Immunosuppression in De Novo Liver Tranplantation: Initial Results from the DIAMOND Study. 16th Congress of the European Society for Organ Transplantation; Vienna, Austria, 8-11 September 2013. [Abstract No: LB02].
10. Saliba F, et al. Micafungin as Antifungal Prophylaxis in High-Risk Liver Transplantation: Randomised Multicentre Trial. 16th Congress of the European Society for Organ Transplantation; Vienna, Austria, 8-11 September 2013. [Abstract No: P217].
11. Pappas PG et al. Guidelines for Treatment of Candidiasis. Clin Infect Dis. 2004;38:161-89.
12. Singh N et al. Invasive Aspergillosis in Solid Organ Transplant Recipients. Am J Transpl. 2009;9(4):S180-S191.
13. Abrams et al. Role of tacrolimus prolonged release in the prevention of allograft rejection. Transpl Research and Risk Management, 2010:2 65-70.
14. Valente G, et al. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplant Patients: Effectiveness in a Real-World Setting. Transplantation Proceedings, 45, 1273-1275 (2013).
15. Mycamine Summary of Product Characteristics. Available at http://www.medicines.org.uk/emc/medicine/20997/SPC/Mycamine+50mg+and+100mg+powder+for+solution+for+infusion/#INDICATIONS. Last accessed August 2013.
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
Oct. 21, 2016 04:45 AM EDT Reads: 368
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Oct. 21, 2016 04:30 AM EDT Reads: 3,062
DevOps is speeding towards the IT world like a freight train and the hype around it is deafening. There is no reason to be afraid of this change as it is the natural reaction to the agile movement that revolutionized development just a few years ago. By definition, DevOps is the natural alignment of IT performance to business profitability. The relevance of this has yet to be quantified but it has been suggested that the route to the CEO’s chair will come from the IT leaders that successfully ma...
Oct. 21, 2016 04:30 AM EDT Reads: 16,193
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Oct. 21, 2016 04:15 AM EDT Reads: 1,697
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
Oct. 21, 2016 04:00 AM EDT Reads: 10,923
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Oct. 21, 2016 03:30 AM EDT Reads: 3,727
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Oct. 21, 2016 03:15 AM EDT Reads: 3,834
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
Oct. 21, 2016 03:15 AM EDT Reads: 1,642
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 21, 2016 02:30 AM EDT Reads: 1,204
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Oct. 21, 2016 02:00 AM EDT Reads: 5,897
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
Oct. 21, 2016 01:45 AM EDT Reads: 3,257
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Oct. 21, 2016 01:30 AM EDT Reads: 1,346
The IoT industry is now at a crossroads, between the fast-paced innovation of technologies and the pending mass adoption by global enterprises. The complexity of combining rapidly evolving technologies and the need to establish practices for market acceleration pose a strong challenge to global enterprises as well as IoT vendors. In his session at @ThingsExpo, Clark Smith, senior product manager for Numerex, will discuss how Numerex, as an experienced, established IoT provider, has embraced a ...
Oct. 21, 2016 01:30 AM EDT Reads: 863
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue an...
Oct. 21, 2016 01:15 AM EDT Reads: 2,909
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Oct. 21, 2016 12:30 AM EDT Reads: 903